替奈普酶静脉溶栓联合取栓对比单纯取栓的疗效与安全性
本研究基于两项全国性真实世界登记数据的回顾性汇总分析,纳入前循环大血管闭塞卒中且症状发作4.5小时内、无溶栓禁忌的患者1890例,比较替奈普酶静脉溶栓联合血管内取栓与单纯取栓的疗效和安全性。结果显示联合治疗与更好的3个月功能预后相关,且不增加症状性颅内出血风险,获益不随时间变化,支持早期时间窗内常规使用替奈普酶。
要点
- 前循环大血管闭塞4.5小时内,替奈普酶联合取栓较单纯取栓改善3个月功能预后
- 联合治疗不增加症状性颅内出血和脑实质血肿风险
- 联合治疗获益与发病至溶栓时间无显著交互作用,不呈时间依赖性
核心结论
- 在症状发作4.5小时内治疗的患者中,替奈普酶联合取栓与单纯取栓相比功能预后更好,且无安全性顾虑。
- 该获益似乎不依赖于治疗时间,支持早期时间窗内取栓前常规使用替奈普酶。
研究设计与样本
- 回顾性汇总分析两项全国性真实世界登记研究(TETRIS和ETIS),纳入前循环大血管闭塞卒中且症状发作4.5小时内、无溶栓禁忌的患者。
- 共分析1890例患者,其中替奈普酶联合取栓组798例,单纯取栓组1092例;中位年龄73岁(四分位距61-82),女性占49.6%。
- 采用倾向评分加权逻辑回归评估治疗组与结局的关联。
主要发现
- 替奈普酶联合取栓组3个月改良Rankin量表(mRS)整体分布优于单纯取栓组(加权共同OR 1.53,95%CI 1.29-1.82,p<0.001)。
- 功能独立(mRS≤2)的倾向评分重叠加权OR为1.50(95%CI 1.23-1.84,p<0.001),支持联合治疗。
- 脑实质血肿发生率无显著差异(PSOW-OR 1.29,95%CI 0.94-1.79,p=0.12)。
- 症状性颅内出血发生率无显著差异(PSOW-OR 1.13,95%CI 0.69-1.86,p=0.61)。
- 首诊于初级或综合卒中中心对疗效无显著交互作用(p-interaction=0.12),预期发病至溶栓时间对疗效也无显著交互作用(p-interaction=0.11)。
关键数值与推荐
- 疗效结局为3个月mRS评分,采用序贯分析和二分类(mRS≤2)分析。
- 中位预期发病至溶栓时间为146分钟(四分位距119-180)。
- 56.2%(1063例)患者首诊于初级卒中中心。
临床怎么用
- 对于前循环大血管闭塞且症状发作4.5小时内的卒中患者,可考虑在血管内取栓前常规静脉给予替奈普酶。
- 联合治疗不增加症状性颅内出血风险,且获益不依赖于发病至溶栓时间,支持早期时间窗内的应用。
局限性
- 本研究为回顾性汇总分析,非随机对照试验,可能存在残余混杂。
- 数据来源于两项真实世界登记研究,治疗决策和患者选择可能存在中心间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. METHODS: We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. RESULTS: Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82]; p < 0.001) and regarding functional independence (propensity score overlap weighting [PSOW]-OR 1.50 [95% CI 1.23-1.84]; p < 0.001). This benefit did not differ statistically between patients admitted first to a primary or comprehensive stroke center (p-interaction = 0.12). There was no significant effect of the expected onset-to-thrombolysis time on the association between TNK + EVT and better functional outcome (p-interaction = 0.11). There were no significant differences in parenchymal hematoma (PSOW-OR 1.29 [95% CI 0.94-1.79]; p = 0.12) and symptomatic intracerebral hemorrhage (PSOW-OR 1.13 [95% CI 0.69-1.86]; p = 0.61) rates. DISCUSSION: Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. TRIALS REGISTRATION INFORMATION: NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).
引用
- Gerschenfeld G, Lapergue B, Seners P, et al. IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion. Neurology. 2026. PMID: 41678809. doi:10.1212/WNL.0000000000214702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。